{"id":8797,"date":"2022-02-22T10:04:14","date_gmt":"2022-02-22T09:04:14","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=8797"},"modified":"2022-02-22T10:04:41","modified_gmt":"2022-02-22T09:04:41","slug":"andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/","title":{"rendered":"Andera Partners accompagne TargED Biopharmaceuticals dans son financement de s\u00e9rie A de 39 millions d\u2019euros afin de proposer un traitement thrombolytique r\u00e9volutionnaire aux patients."},"content":{"rendered":"<p>TargED Biopharmaceuticals (\u00ab\u00a0TargED\u00a0\u00bb), une soci\u00e9t\u00e9 priv\u00e9e de biotechnologie ax\u00e9e sur le d\u00e9veloppement d&rsquo;un compos\u00e9 au nouveau mode d\u2019action pour le traitement des maladies thrombotiques, annonce aujourd&rsquo;hui qu&rsquo;elle a lev\u00e9 39 millions d&rsquo;euros en financement de s\u00e9rie A pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son compos\u00e9 principal, Microlyse. Le financement a \u00e9t\u00e9 men\u00e9 \u00e0 parts \u00e9gales par un syndicat international comprenant Andera Partners, Fund+, Hadean Ventures, Inkef Capital et Sunstone Life Science Ventures, et rejoint par les investisseurs existants FIRST (g\u00e9r\u00e9 par BioGeneration Ventures), Curie Capital et Utrecht Health Seed Fund. TargED se concentrera sur deux indications initiales : le purpura thrombotique thrombocytop\u00e9nique acquis (aTTP) et l&rsquo;accident vasculaire c\u00e9r\u00e9bral isch\u00e9mique aigu (AIS).<\/p>\n<p>Le produit phare de TargED, Microlyse, est un compos\u00e9 propri\u00e9taire et au m\u00e9canisme d\u2019action unique, qui brise les caillots sanguins en se liant \u00e0 une prot\u00e9ine pr\u00e9sente dans les caillots sanguins de toutes les formes de thromboses. Microlyse est le premier compos\u00e9 \u00e0 permettre l&rsquo;administration cibl\u00e9e d&rsquo;enzymes, en utilisant un anticorps \u00e0 domaine unique (VhH), directement sur les caillots sanguins. En raison de la nature cibl\u00e9e de la th\u00e9rapie, on s&rsquo;attend \u00e0 ce qu&rsquo;elle pr\u00e9sente un profil d&rsquo;effets secondaires sup\u00e9rieur, ainsi qu&rsquo;un potentiel d\u2019efficacit\u00e9 exceptionnel par rapport aux agents actuels. Le m\u00e9canisme d&rsquo;action unique de Microlyse permet des applications potentielles dans une vari\u00e9t\u00e9 d&rsquo;indications impliquant la thrombose, y compris la maladie potentiellement mortelle de l\u2019aTTP. Les travaux novateurs d\u00e9montrant que Microlyse cible sp\u00e9cifiquement les caillots sanguins, entra\u00eenant leur dissolution plus rapide et plus s\u00fbre que les soins standard, ont r\u00e9cemment fait la couverture de la revue Blood. (<a href=\"https:\/\/ashpublications.org\/blood\/article-abstract\/139\/4\/597\/477915\/Microlyse-a-thrombolytic-agent-that-targets-VWF?redirectedFrom=fulltext\">Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis<\/a>).<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Kristof Vercruysse, pr\u00e9sident-directeur g\u00e9n\u00e9ral de TargED, a d\u00e9clar\u00e9<\/strong> : <em>\u00ab\u00a0Nous sommes ravis d&rsquo;avoir le soutien de ce syndicat international d&rsquo;investisseurs en sciences de la vie de classe mondiale, une validation du potentiel de Microlyse. Nous sommes fiers de d\u00e9velopper des produits qui ont le potentiel d&rsquo;avoir un impact positif sur des millions de vies en permettant l&rsquo;acc\u00e8s des patients \u00e0 un tel traitement salvateur.\u00a0\u00bb<\/em><\/p>\n<p>A la cl\u00f4ture de ce financement, le Board de TargED inclura Thijs Cohen Tervaert, Inkef Capital (Chair); Olivier Litzka, Andera Partners; Mariette van der Velden-Roesink, Curie Capital; Jan Van den Bossche, Fund+; Roger Franklin, Hadean Ventures; and Jacob Lange Moresco, Sunstone Life Science Ventures.<\/p>\n<p><strong>\u00a0<\/strong><strong>Olivier Litzka, Associ\u00e9 chez Andera Partners a d\u00e9clar\u00e9 :<\/strong> <em>\u00ab\u00a0Avec Jacob, Roger, Jan et Thijs, nous sommes tr\u00e8s impressionn\u00e9s par ce que l&rsquo;\u00e9quipe de TargED a r\u00e9alis\u00e9 jusqu&rsquo;\u00e0 pr\u00e9sent et sommes tr\u00e8s heureux d\u2019investir dans cette \u00e9quipe. Microlyse est une innovation th\u00e9rapeutique qui a un tr\u00e8s fort potentiel pour r\u00e9duire de mani\u00e8re significative le poids des maladies li\u00e9es aux \u00e9v\u00e9nements thrombotiques. Nous sommes enthousiasm\u00e9s de joindre nos forces \u00e0 TargED pour acc\u00e9l\u00e9rer le d\u00e9veloppement de Microlyse en clinique, \u00e0 la fois dans le purpura thrombotique thrombocytop\u00e9nique acquis (aTTP) et dans l&rsquo;accident vasculaire c\u00e9r\u00e9bral isch\u00e9mique aigu (AIS)\u00a0\u00bb.<\/em><\/p>\n<p><em>\u00ab\u00a0Nous sommes heureux que nos efforts pionniers sur la conception d&rsquo;une enzyme qui cible les caillots sanguins aient conduit \u00e0 des donn\u00e9es pr\u00e9cliniques convaincantes r\u00e9cemment publi\u00e9es dans la revue Blood\u00a0\u00bb, <\/em><strong>a d\u00e9clar\u00e9 le professeur associ\u00e9 de l&rsquo;UMC Utrecht Coen Maas et cofondateur scientifique de TargED.<\/strong><em> \u00ab\u00a0Il est passionnant de voir que ce travail a \u00e9t\u00e9 en mesure d&rsquo;attirer un syndicat d&rsquo;investisseurs aussi puissant, qui va maintenant nous permettre de d\u00e9velopper Microlyse vers une perc\u00e9e th\u00e9rapeutique, potentiellement dans une gamme d&rsquo;indications avec un besoin m\u00e9dical non satisfait \u00e9lev\u00e9\u00a0\u00bb.<\/em><\/p>\n<p><em>\u00a0<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>TargED Biopharmaceuticals (\u00ab\u00a0TargED\u00a0\u00bb), une soci\u00e9t\u00e9 priv\u00e9e de biotechnologie ax\u00e9e sur le d\u00e9veloppement d&rsquo;un compos\u00e9 au nouveau mode d\u2019action pour le traitement des maladies thrombotiques, annonce aujourd&rsquo;hui qu&rsquo;elle a lev\u00e9 39 millions d&rsquo;euros en financement de s\u00e9rie A pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son compos\u00e9 principal, Microlyse. Le financement a \u00e9t\u00e9 men\u00e9 \u00e0 parts \u00e9gales par&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[78],"class_list":["post-8797","post","type-post","status-publish","format-standard","hentry","category-biodiscovery"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Andera Partners accompagne TargED Biopharmaceuticals dans son financement de s\u00e9rie A de 39 millions d\u2019euros afin de proposer un traitement thrombolytique r\u00e9volutionnaire aux patients. - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Andera Partners accompagne TargED Biopharmaceuticals dans son financement de s\u00e9rie A de 39 millions d\u2019euros afin de proposer un traitement thrombolytique r\u00e9volutionnaire aux patients. - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"TargED Biopharmaceuticals (\u00ab\u00a0TargED\u00a0\u00bb), une soci\u00e9t\u00e9 priv\u00e9e de biotechnologie ax\u00e9e sur le d\u00e9veloppement d&rsquo;un compos\u00e9 au nouveau mode d\u2019action pour le traitement des maladies thrombotiques, annonce aujourd&rsquo;hui qu&rsquo;elle a lev\u00e9 39 millions d&rsquo;euros en financement de s\u00e9rie A pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son compos\u00e9 principal, Microlyse. Le financement a \u00e9t\u00e9 men\u00e9 \u00e0 parts \u00e9gales par...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-22T09:04:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-22T09:04:41+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Andera Partners accompagne TargED Biopharmaceuticals dans son financement de s\u00e9rie A de 39 millions d\u2019euros afin de proposer un traitement thrombolytique r\u00e9volutionnaire aux patients.\",\"datePublished\":\"2022-02-22T09:04:14+00:00\",\"dateModified\":\"2022-02-22T09:04:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/\"},\"wordCount\":668,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/\",\"name\":\"Andera Partners accompagne TargED Biopharmaceuticals dans son financement de s\u00e9rie A de 39 millions d\u2019euros afin de proposer un traitement thrombolytique r\u00e9volutionnaire aux patients. - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2022-02-22T09:04:14+00:00\",\"dateModified\":\"2022-02-22T09:04:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Andera Partners accompagne TargED Biopharmaceuticals dans son financement de s\u00e9rie A de 39 millions d\u2019euros afin de proposer un traitement thrombolytique r\u00e9volutionnaire aux patients.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Andera Partners accompagne TargED Biopharmaceuticals dans son financement de s\u00e9rie A de 39 millions d\u2019euros afin de proposer un traitement thrombolytique r\u00e9volutionnaire aux patients. - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/","og_locale":"fr_FR","og_type":"article","og_title":"Andera Partners accompagne TargED Biopharmaceuticals dans son financement de s\u00e9rie A de 39 millions d\u2019euros afin de proposer un traitement thrombolytique r\u00e9volutionnaire aux patients. - ANDERA PARTNERS","og_description":"TargED Biopharmaceuticals (\u00ab\u00a0TargED\u00a0\u00bb), une soci\u00e9t\u00e9 priv\u00e9e de biotechnologie ax\u00e9e sur le d\u00e9veloppement d&rsquo;un compos\u00e9 au nouveau mode d\u2019action pour le traitement des maladies thrombotiques, annonce aujourd&rsquo;hui qu&rsquo;elle a lev\u00e9 39 millions d&rsquo;euros en financement de s\u00e9rie A pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son compos\u00e9 principal, Microlyse. Le financement a \u00e9t\u00e9 men\u00e9 \u00e0 parts \u00e9gales par...","og_url":"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2022-02-22T09:04:14+00:00","article_modified_time":"2022-02-22T09:04:41+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Andera Partners accompagne TargED Biopharmaceuticals dans son financement de s\u00e9rie A de 39 millions d\u2019euros afin de proposer un traitement thrombolytique r\u00e9volutionnaire aux patients.","datePublished":"2022-02-22T09:04:14+00:00","dateModified":"2022-02-22T09:04:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/"},"wordCount":668,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/","url":"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/","name":"Andera Partners accompagne TargED Biopharmaceuticals dans son financement de s\u00e9rie A de 39 millions d\u2019euros afin de proposer un traitement thrombolytique r\u00e9volutionnaire aux patients. - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2022-02-22T09:04:14+00:00","dateModified":"2022-02-22T09:04:41+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-accompagne-targed-biopharmaceuticals-dans-son-financement-de-serie-a-de-39-millions-deuros-afin-de-proposer-un-traitement-thrombolytique-revolutionnaire-aux-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Andera Partners accompagne TargED Biopharmaceuticals dans son financement de s\u00e9rie A de 39 millions d\u2019euros afin de proposer un traitement thrombolytique r\u00e9volutionnaire aux patients."}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/8797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=8797"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/8797\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=8797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=8797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}